← 홈

다발성 골수종

259개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-14 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 259개
AntibodyPfizerPhase 3

Elotuzumab (Elotuzumab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#인기#항체+4
효능 ORR 100%임상시험 57상태 RECRUITING
CGTBiologicMinsk Scientific-Practical Cent…Phase 2

Anti-BCMA CAR-T cells (Anti-BCMA CAR-T cells)

Multiple Myeloma Refractory · BCMA

#BCMA#CGT#Phase2#인기#세포유전치료+5
효능 ORR 97.1%임상시험 56상태 RECRUITING
AntibodyIndapta Therapeutics, INC.Phase 3

Isatuximab (Isatuximab)

NHL; Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase3#인기#항체+5
효능 ORR 67%임상시험 56상태 RECRUITING
ADCBiologicFortis Therapeutics, Inc.Phase 2

FOR46 (FOR46)

Multiple Myeloma; Multiple Myeloma in Relapse · Prostate Cancer Metastatic

#ProstateCancerMetastatic#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 51.5%임상시험 55상태 RECRUITING
CGTBiologicCarbiogene Therapeutics Co. Ltd.Phase 1

anti-BCMA CAR-T (anti-BCMA CAR-T)

Multiple Myeloma · BCMA

#BCMA#CGT#Phase1#인기#세포유전치료+5
효능 ORR 97.1%임상시험 55상태 ACTIVE
AntibodyPfizerApproved

Elranatamab (Elranatamab)

Multiple Myeloma · FRα

#FR#Antibody#Approved#인기#항체+5
효능 ORR 61%임상시험 54상태 RECRUITING
AntibodyRegeneronPhase 2

Cemiplimab REGN2810 (Cemiplimab REGN2810)

Plasma Cell Myeloma · Prostate Cancer

#ProstateCancer#Antibody#Phase2#인기#항체+5
효능 ORR 55.6%임상시험 51상태 ACTIVE
AntibodyPfizerPhase 2

PF-06863135 (Elranatamab, Elranatamab (PF-06863135))

Multiple Myeloma · FRα

#FR#Antibody#Phase2#인기#항체+5
효능 ORR 61%임상시험 51상태 ACTIVE
ADCBiologicPfizerPhase 3

Iberdomide (Iberdomide)

Multiple Myeloma · FRα

#FR#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 92.9%임상시험 47상태 RECRUITING
AntibodyJack Khouri, MDPhase 2

Siltuximab (Siltuximab)

Multiple Myeloma; Cytokine Release Syndrome · Myelofibrosis

#Myelofibrosis#Antibody#Phase2#항체#면역항체+5
효능 ORR 46.7%임상시험 43상태 RECRUITING
AntibodyJanssenPhase 3

Talquetamab (Talquetamab)

Myeloma Multiple; Plasma Cell Leukemia · FRα

#FR#Antibody#Phase3#항체#면역항체+5
임상시험 40상태 DISCONTINUED
CGTBiologicSung-Soo ParkPreclinical

IMiD treatment (IMiD treatment)

Multiple Myeloma, Relapsed; Multiple Myeloma (MM) · FRα

#FR#CGT#Preclinical#세포유전치료#CAR-T+5
효능 ORR 48.3%임상시험 39상태 RECRUITING
ADCBiologicSanofiPhase 2

Belumosudil (Belumosudil)

Plasma Cell Myeloma Refractory · FRα

#FR#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 74%임상시험 38상태 RECRUITING
ADCBiologicJanssen Research & Development,…Phase 2

Nirogacestat (Nirogacestat)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 57%임상시험 32상태 RECRUITING
AntibodyBristol Myers SquibbPhase 2

nivolumab (Opdivo, Nivolumab plus Ipilimumab)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+5
효능 ORR 77.8%임상시험 32상태 RECRUITING
AntibodyRochederuxtecan, are effective i…Phase 2

trastuzumab (Herceptin, Trastuzumab plus Pertuzumab)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+5
효능 ORR 79.5%임상시험 32상태 RECRUITING
AntibodystaleSanofiPhase 3

Isatuximab SAR650984 (Isatuximab SAR650984)

Immune System Disorder · Plasma Cell Myeloma

#PlasmaCellMyeloma#Antibody#Phase3#항체#면역항체+3
효능 ORR 55.6%임상시험 31상태 ACTIVE
AntibodystaleRochePhase 2

trastuzumab (Herceptin, Trastuzumab and Pertuzumab)

Lymphoma, Non-Hodgkin; Multiple Myeloma · Lymphoma, Non-Hodgkin

#LymphomaNon-Hodgkin#Antibody#Phase2#항체#면역항체+5
효능 ORR 69.3%임상시험 31상태 RECRUITING
CGTBiologicstalePoseida Therapeutics, Inc.Phase 2

autologous anti-BCMA chimeric antigen receptor T cells (autologous anti-BCMA chimeric antigen receptor T cells)

ITP · BCMA

#BCMA#CGT#Phase2#세포유전치료#CAR-T+3
효능 ORR 96.6%임상시험 31상태 ACTIVE
CGTBiologicChinese PLA General HospitalPhase 2

Anti-BCMA-CD19 CAR-T cells (Anti-BCMA-CD19 CAR-T cells)

IgG4 Related Disease; B-cell Mediated Autoimmune Disorders · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+5
임상시험 30상태 RECRUITING

2 / 13 페이지

← 이전다음 →